Analysis of the Aggregative Cases of Adverse Drug Reactions/Events in Our Hospital

Chinese Journal of Pharmacovigilance ›› 2012, Vol. 9 ›› Issue (10): 615-618.

• Orginal Article • Previous Articles Next Articles

Analysis of the Aggregative Cases of Adverse Drug Reactions/Events in Our Hospital

LI Lei, LIU Jing, WU Wen

Department of Pharmacy, the First People's Hospital, Anhui Hefei 230061, China

Received:2012-03-31 Online:2012-10-10 Published:2015-08-07

Abstract

Abstract: The aggregative cases of adverse drug reactions/events(ADR/ADE) at our hospital in 2011 were statistically analyzed, and the causes were explained. Suggestions were given to reduce the damage induced by ADR/ADE. Intensive monitoring was given to the related clinical departments and largely used drugs to ensure the patients' medication safety.

Key words: aggregative, ADR, ADE, intensive monitoring, rational drug use

LI Lei, LIU Jing, WU Wen. Analysis of the Aggregative Cases of Adverse Drug Reactions/Events in Our Hospital[J]. Chinese Journal of Pharmacovigilance, 2012, 9(10): 615-618.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2012/V9/I10/615

[1]	LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou. Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
[2]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[3]	YANG Xin, YANG Baochun, YANG Yang, SHAO Huan. One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
[4]	QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
[5]	TANG Jiong, ZENG Yuqi. One Case of Oculomotor Paralysis Caused by Sugemalimab Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 812-814.
[6]	LI Min, LI Chunlei, SUN Cuicui, YU Wenwen, SUN Qing, QI Yingmei, LIU Anchang. One Case of Acute Generalized Exanthematous Pustulosis Caused by Abrocitinib Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 823-825.
[7]	ZHENG Sili, ZHANG Xiaoqing. 133 Cases of Adverse Drug Reactions in Female Patients [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 654-658.
[8]	WANG Hao, MA Jinfu, MA Rui, LI Xiaogang, ZHAO Qiang, ZHANG Xian. One Case of Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium for Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 686-688.
[9]	WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping. Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
[10]	MEI Liping, BAI Fuchen, YU Jie, ZHANG Chunjie, WANG Yajun, AN Limei. Determinants of Blood Drug Concentration / Dose Ratio of Antipsychotics [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 424-428.
[11]	LIU Yalan, LIU Yanxiang, CHEN Peng. One Case of Vitiligo Caused by Sintilimab Injection in a Patient with Advanced Long-Term Survival Lung Adenocarcinoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 460-462.
[12]	ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning. Words of Warning and Preventive Measures in Labels of Antidepressants [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
[13]	WANG Hongli, DU Juan, CAO Mengqi, ZHANG Luyong, JIANG Zhenzhou, HUANG Xin. Effects of Triptolide on Secretion of Steroid Hormone in Primary Adrenocortical Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 139-146.
[14]	LI Bo, XU Liu, XIE Yuqing, WANG Yiying, DONG Shuai, LIAN Jie, LI Guodong, CAO Huijuan. Safety and Efficacy of Chinese Herbal Patent Medicines for COVID-19: an Umbrella Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 155-161.
[15]	ZHOU Kun, MA Liang, LI Zhaofeng, CAO Bing, GU Hongwei, LIU Qian. Usage of Nerve-Calming Chinese Herbal Patent Medicines in a Mental Health Center [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 211-216.

Analysis of the Aggregative Cases of Adverse Drug Reactions/Events in Our Hospital

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics